A PYMNTS Company

UK: AstraZeneca strikes $600 million deal with Dublin-based Actavis

By  |  February 5, 2015

AstraZeneca said on Thursday it would buy Actavis’ branded respiratory drug business in the United States and Canada for an initial $600 million.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The U.K. drug maker is seeking to boost its pipeline through deals and partnerships, and has been bulking up its respiratory drug business. Last year they made a deal to buy a portfolio of inhaled drugs from Spanish Almirall.

     

    Full Content: The Financial Times

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.